These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17410321)

  • 1. Interaction between estrogen receptor-alpha and butyrylcholinesterase genes modulates Alzheimer's disease risk.
    Combarros O; Riancho JA; Arozamena J; Mateo I; Llorca J; Infante J; Sánchez-Juan P; Zarrabeitia MT; Berciano J
    J Neurol; 2007 Sep; 254(9):1290-2. PubMed ID: 17410321
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
    Combarros O; Riancho JA; Infante J; Sañudo C; Llorca J; Zarrabeitia MT; Berciano J
    Dement Geriatr Cogn Disord; 2005; 20(2-3):153-7. PubMed ID: 16020944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
    Déniz-Naranjo MC; Muñoz-Fernández C; Alemany-Rodríguez MJ; del Carmen Pérez-Vieitez M; Aladro-Benito Y; Irurita-Latasa J; Sánchez-García F
    Neurosci Lett; 2007 Oct; 427(1):34-8. PubMed ID: 17923322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk.
    Mateo I; Llorca J; Infante J; Rodríguez-Rodríguez E; Berciano J; Combarros O
    Eur J Neurol; 2008 Mar; 15(3):219-22. PubMed ID: 18290843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females.
    Porrello E; Monti MC; Sinforiani E; Cairati M; Guaita A; Montomoli C; Govoni S; Racchi M
    Eur J Neurol; 2006 Jun; 13(6):639-44. PubMed ID: 16796589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
    Tilley L; Morgan K; Grainger J; Marsters P; Morgan L; Lowe J; Xuereb J; Wischik C; Harrington C; Kalsheker N
    Eur J Hum Genet; 1999 Sep; 7(6):659-63. PubMed ID: 10482954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K variant of butyrycholinesterase and late-onset Alzheimer's disease.
    Russ C; Powell J; Lovestone S; Holmes C
    Lancet; 1998 Mar; 351(9106):881. PubMed ID: 9525372
    [No Abstract]   [Full Text] [Related]  

  • 8. Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans.
    Kim KW; Jhoo JH; Lee JH; Lee KU; Lee DY; Youn JC; Youn JY; Woo JI
    J Neural Transm (Vienna); 2001; 108(10):1159-66. PubMed ID: 11725818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
    Raygani AV; Zahrai M; Soltanzadeh A; Doosti M; Javadi E; Pourmotabbed T
    Neurosci Lett; 2004 Nov; 371(2-3):142-6. PubMed ID: 15519745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
    Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
    J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age at onset: an essential variable for the definition of genetic risk factors for sporadic Alzheimer's disease.
    Beyer K; Lao JI; Latorre P; Ariza A
    Ann N Y Acad Sci; 2005 Dec; 1057():260-78. PubMed ID: 16399900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density.
    Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Mijares V; González-Macías J
    Eur J Endocrinol; 2006 Jul; 155(1):53-9. PubMed ID: 16793950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of estrogen receptor-α and receptor-β gene polymorphisms on Alzheimer's disease.
    Goumidi L; Dahlman-Wright K; Tapia-Paez I; Matsson H; Pasquier F; Amouyel P; Kere J; Lambert JC; Meirhaeghe A
    J Alzheimers Dis; 2011; 26(3):431-9. PubMed ID: 21673408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor 1 PvuII and XbaI polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis.
    Lee YH; Song GG
    Genet Mol Res; 2015 Aug; 14(3):9361-9. PubMed ID: 26345870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.
    Ballard C; Morris C; Kalaria R; McKeith I; Perry R; Perry E
    Dement Geriatr Cogn Disord; 2005; 19(5-6):357-60. PubMed ID: 15802910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.
    Lane RM; He Y
    Alzheimers Dement; 2013 Mar; 9(2):e1-73. PubMed ID: 22402324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease.
    Ishunina TA; Fischer DF; Swaab DF
    Neurobiol Aging; 2007 Nov; 28(11):1670-81. PubMed ID: 17010478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
    Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A
    Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP19 haplotypes increase risk for Alzheimer's disease.
    Huang R; Poduslo SE
    J Med Genet; 2006 Aug; 43(8):e42. PubMed ID: 16882736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
    Patterson CE; Todd SA; Passmore AP
    Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.